DataLibraryResearch is tracking the market dynamics of the crisis in the Pharma & Healthcare industry amid lock-down changes in the supply chain.

Get detailed analysis of the COVID-19 impact on the Pneumonia Vaccines Market

Global Pneumonia Vaccines Market Opportunities and Forecast 2020-2027

  • DLR2623
  • 17 September, 2021
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Pneumonia Vaccines Market, By Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine), By Product Type (Prevnar 13, Synflorix, Pneumovax 23), By Sector (Public, Private), By Distribution Channel (Distribution Partner Companies, Non-governmental Organizations (NGO), Government Authorities), and opportunities and forecast 2020-2027

Pneumonia Vaccines Market Overview

Pneumonia is an infection of one or both of the lungs caused by bacteria, viruses, or fungi. It is a serious infection in which the air sacs fill with pus and other liquid. Lobar pneumonia affects one or more sections (lobes) of the lungs. Infants below the age of two years and adults over the age of 65 years are at a higher risk of acquiring pneumonia. Pneumonia vaccine helps in fighting and provides immunization against over 13 types of pneumococcal bacteria known to cause infection in the lungs.
 
According to World Health Organization, Pneumonia is the single largest infectious cause of death in children worldwide. Pneumonia killed 808 694 children under the age of 5 in 2017, accounting for 15% of all deaths of children under five years old. Pneumonia affects children and families everywhere but is most prevalent in South Asia and sub-Saharan Africa.  Therefore, the high prevalence of pneumonia in children worldwide contributes to the growth of the global Pneumonia Vaccines market. Furthermore, the growing old age population along with the increasing incidence of pneumococcal infections, makes the aging population more prone to infections, contributing to the increase in demand for pneumonia vaccines. This factor further escalates the growth of the global Pneumonia Vaccines market.
 
Additionally, people with a weakened immune system, also people suffering from heart disease, diabetes, smokers, and heavy drinkers, are more likely to get pneumonia. Growth in the population with weakened immune systems contributes to the demand for the pneumonia vaccine. This key factor majorly supports the growth of the global Pneumonia Vaccines market.
 
Covid-19 Impact on Pneumonia Vaccines Market
 
In addition, the current Pneumonia Vaccines Market study offers a detailed analysis of the current COVID-19 pandemic impact on the market growth and its influence on the future growth of the Pneumonia Vaccines Market. The recently published report demonstrates the elevation in the demand for the healthcare sector. The healthcare manufacturers have experienced long term as well as short term effect which includes supply shortages, panic buying, and stocking, regulation changes as short-term whereas approval delays and possible trend variations in consumption could be perceived as long-term impacts of COVID-19 on the health and pharmaceutical market.

The increasing need for a cure has pushed vaccine research and manufacturers to the limit. In addition to this, panic conditions have already spurred the demand for many healthcare products and services which are discussed in detail in this report. Moreover, the impact of COVID-19 on overall market revenue for the base year 2020 and its projection up to 2027 is provided in detail in this report.

Pneumonia Vaccines Market Segment Overview
 
Based on Vaccine Type, the Pneumococcal Conjugate Vaccine segment is the largest contributor to the global Pneumonia Vaccine market and is projected to maintain its dominant position over the stated period. These vaccines can immunize infants and children from 6 weeks to 5 years of age to prevent invasive disease, pneumonia, and acute otitis media. Additionally, the Pneumococcal Polysaccharide Vaccine segment is the fastest-growing segment of the market. This is due to the Pneumovax 23 is proven efficacious against invasive pneumonia disease in healthy young adults. It is mainly indicated to use in the population aged 50 years and above and population aged more than 2 years.
 
Pneumonia Vaccines Market, By Vaccine Type
·       Pneumococcal Conjugate Vaccine
·       Pneumococcal Polysaccharide Vaccine
 
Pneumonia Vaccines Market, By Product Type
·       Prevnar 13
·       Synflorix
·       Pneumovax 23

Pneumonia Vaccines Market, By Sector
·       Public
·       Private
 
Pneumonia Vaccines Market, By Distribution Channel
·       Distribution Partner Companies
·       Non-governmental Organizations (NGO)
·       Government Authorities
 
Pneumonia Vaccines Market Regional Overview

Geographically, North America dominated the global Pneumonia Vaccine market. This is due to the strong presence of leading market players, high prevalence of pneumonia, increasing government focus on immunization programs, and advancements in the administration of vaccines in this region. Europe was the second-largest market for the pneumonia vaccine. Similarly, Asia Pacific is expected to be the fastest-growing market for the pneumonia vaccine. The rising focus of the governments in countries in Asia on enhancing healthcare facilities, government initiatives, increasing disposable income, and rapid economic development contribute to the growth of the Pneumonia Vaccine market in this region.
 
Pneumonia Vaccines Market, By Geography
 
·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, Russia & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Pneumonia Vaccines Market, Key Players

·       Glaxosmithkline plc.
·       LG Chem Ltd.
·       Merck & Co., Inc.
·       Panacea Biotec Limited
·       Pfizer Inc.
·       Pnuvax Incorporated
·       Serum Institute of India Pvt. Ltd.
·       Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)
·       SK Bioscience
·       Walvax Biotechnology Co., Ltd.

Pneumonia Vaccines Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Vaccine Type
        • 5.2.1. Pneumococcal Conjugate Vaccine
        • 5.2.2. Pneumococcal Polysaccharide Vaccine
      • 5.3. Market Analysis, Insights and Forecast – By Product Type
        • 5.3.1. Prevnar 13
        • 5.3.2. Synflorix
        • 5.3.3. Pneumovax 23
      • 5.4. Market Analysis, Insights and Forecast – By Sector
        • 5.4.1. Public
        • 5.4.2. Private
      • 5.5. Market Analysis, Insights and Forecast – By Distribution Channel
        • 5.5.1. Distribution Partner Companies
        • 5.5.2. Non-governmental Organizations (NGO)
        • 5.5.3. Government Authorities
      • 5.6. Market Analysis, Insights and Forecast – By Region
        • 5.6.1. North America
        • 5.6.2. Europe
        • 5.6.3. Asia Pacific
        • 5.6.4. Latin America, Middle East and Africa

      6. North America Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Vaccine Type
        • 6.2.1. Pneumococcal Conjugate Vaccine
        • 6.2.2. Pneumococcal Polysaccharide Vaccine
      • 6.3. Market Analysis, Insights and Forecast – By Product Type
        • 6.3.1. Prevnar 13
        • 6.3.2. Synflorix
        • 6.3.3. Pneumovax 23
      • 6.4. Market Analysis, Insights and Forecast – By Sector
        • 6.4.1. Public
        • 6.4.2. Private
      • 6.5. Market Analysis, Insights and Forecast – By Distribution Channel
        • 6.5.1. Distribution Partner Companies
        • 6.5.2. Non-governmental Organizations (NGO)
        • 6.5.3. Government Authorities
      • 6.6. Market Analysis, Insights and Forecast – By Country
        • 6.6.1. U.S.
        • 6.6.2. Canada

      7. Europe Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Vaccine Type
        • 7.2.1. Pneumococcal Conjugate Vaccine
        • 7.2.2. Pneumococcal Polysaccharide Vaccine
      • 7.3. Market Analysis, Insights and Forecast – By Product Type
        • 7.3.1. Prevnar 13
        • 7.3.2. Synflorix
        • 7.3.3. Pneumovax 23
      • 7.4. Market Analysis, Insights and Forecast – By Sector
        • 7.4.1. Public
        • 7.4.2. Private
      • 7.5. Market Analysis, Insights and Forecast – By Distribution Channel
        • 7.5.1. Distribution Partner Companies
        • 7.5.2. Non-governmental Organizations (NGO)
        • 7.5.3. Government Authorities
      • 7.6. Market Analysis, Insights and Forecast – By Country
        • 7.6.1. UK
        • 7.6.2. Germany
        • 7.6.3. France
        • 7.6.4. Italy
        • 7.6.5. Spain
        • 7.6.6. Russia
        • 7.6.7. Rest of Europe

      8. Asia Pacific Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Vaccine Type
        • 8.2.1. Pneumococcal Conjugate Vaccine
        • 8.2.2. Pneumococcal Polysaccharide Vaccine
      • 8.3. Market Analysis, Insights and Forecast – By Product Type
        • 8.3.1. Prevnar 13
        • 8.3.2. Synflorix
        • 8.3.3. Pneumovax 23
      • 8.4. Market Analysis, Insights and Forecast – By Sector
        • 8.4.1. Public
        • 8.4.2. Private
      • 8.5. Market Analysis, Insights and Forecast – By Distribution Channel
        • 8.5.1. Distribution Partner Companies
        • 8.5.2. Non-governmental Organizations (NGO)
        • 8.5.3. Government Authorities
      • 8.6. Market Analysis, Insights and Forecast – By Country
        • 8.6.1. China
        • 8.6.2. India
        • 8.6.3. Japan
        • 8.6.4. Australia
        • 8.6.5. South East Asia
        • 8.6.6. Rest of Asia Pacific

      9. Latin America, Middle East and Africa Pneumonia Vaccines Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Vaccine Type
        • 9.2.1. Pneumococcal Conjugate Vaccine
        • 9.2.2. Pneumococcal Polysaccharide Vaccine
      • 9.3. Market Analysis, Insights and Forecast – By Product Type
        • 9.3.1. Prevnar 13
        • 9.3.2. Synflorix
        • 9.3.3. Pneumovax 23
      • 9.4. Market Analysis, Insights and Forecast – By Sector
        • 9.4.1. Public
        • 9.4.2. Private
      • 9.5. Market Analysis, Insights and Forecast – By Distribution Channel
        • 9.5.1. Distribution Partner Companies
        • 9.5.2. Non-governmental Organizations (NGO)
        • 9.5.3. Government Authorities
      • 9.6. Market Analysis, Insights and Forecast – By Country
        • 9.6.1. Brazil
        • 9.6.2. Saudi Arabia
        • 9.6.3. UAE
        • 9.6.4. Rest of LAMEA

      10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. Glaxosmithkline plc.
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. LG Chem Ltd.
      • 10.6. Merck & Co., Inc.
      • 10.7. Panacea Biotec Limited
      • 10.8. Pfizer Inc.
      • 10.9. Pnuvax Incorporated
      • 10.10. Serum Institute of India Pvt. Ltd.
      • 10.11. Shenzhen Kangtai Biological Products Co., Ltd. (Beijing Minhai Biotechnology Corporation Limited)
      • 10.12. SK Bioscience
      List of Figures

      Figure 1: Global Pneumonia Vaccines Market Revenue Breakdown (USD Billion, %) by Region, 2019 & 2027
      Figure 2: Global Pneumonia Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 3: Global Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 4: Global Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 5: Global Pneumonia Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 6: Global Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 7: Global Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 8: Global Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 9: Global Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 10: Global Pneumonia Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 11: Global Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 12: Global Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 13: Global Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 14: Global Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 15: Global Pneumonia Vaccines Market Value (USD Billion), by Region, 2019 & 2027
      Figure 16: North America Pneumonia Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 17: North America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 18: North America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 19: North America Pneumonia Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 20: North America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 21: North America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 22: North America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 23: North America Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 24: North America Pneumonia Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 25: North America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 26: North America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 27: North America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 28: North America Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 29: North America Pneumonia Vaccines Market Forecast (USD Billion), by U.S., 2016-2027
      Figure 30: North America Pneumonia Vaccines Market Forecast (USD Billion), by Canada, 2016-2027
      Figure 31: Latin America Pneumonia Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 32: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 33: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 34: Latin America Pneumonia Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 35: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 36: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 37: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 38: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 39: Latin America Pneumonia Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 40: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 41: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 42: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 43: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 44: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Brazil, 2016-2027
      Figure 45: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Mexico, 2016-2027
      Figure 46: Latin America Pneumonia Vaccines Market Forecast (USD Billion), by Rest of Latin America, 2016-2027
      Figure 47: Europe Pneumonia Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 48: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 49: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 50: Europe Pneumonia Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 51: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 52: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 53: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 54: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 55: Europe Pneumonia Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 56: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 57: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 58: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 59: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 60: Europe Pneumonia Vaccines Market Forecast (USD Billion), by U.K., 2016-2027
      Figure 61: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Germany, 2016-2027
      Figure 62: Europe Pneumonia Vaccines Market Forecast (USD Billion), by France, 2016-2027
      Figure 63: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Italy, 2016-2027
      Figure 64: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Spain, 2016-2027
      Figure 65: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Russia, 2016-2027
      Figure 66: Europe Pneumonia Vaccines Market Forecast (USD Billion), by Rest of Europe, 2016-2027
      Figure 67: Asia Pacific Pneumonia Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 68: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 69: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 70: Asia Pacific Pneumonia Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 71: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 72: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 73: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 74: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 75: Asia Pacific Pneumonia Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 76: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 77: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 78: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 79: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 80: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by China, 2016-2027
      Figure 81: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by India, 2016-2027
      Figure 82: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Japan, 2016-2027
      Figure 83: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Australia, 2016-2027
      Figure 84: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Southeast Asia, 2016-2027
      Figure 85: Asia Pacific Pneumonia Vaccines Market Forecast (USD Billion), by Rest of Asia Pacific, 2016-2027
      Figure 86: Middle East & Africa Pneumonia Vaccines Market Value Share (%), By Segment 1, 2019 & 2027
      Figure 87: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 88: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 89: Middle East & Africa Pneumonia Vaccines Market Value Share (%), By Segment 2, 2019 & 2027
      Figure 90: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 91: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 92: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 93: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 94: Middle East & Africa Pneumonia Vaccines Market Value Share (%), By Segment 3, 2019 & 2027
      Figure 95: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 1, 2016-2027
      Figure 96: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 2, 2016-2027
      Figure 97: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Sub-Segment 3, 2016-2027
      Figure 98: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Others, 2016-2027
      Figure 99: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by GCC, 2016-2027
      Figure 100: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by South Africa, 2016-2027
      Figure 101: Middle East & Africa Pneumonia Vaccines Market Forecast (USD Billion), by Rest of Middle East & Africa, 2016-2027 
      List of Tables
      Table 1: Global Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 2: Global Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 3: Global Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 4: Global Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Region, 2016-2027
      Table 5: North America Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 6: North America Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 7: North America Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 8: North America Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 9: Europe Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 10: Europe Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 11: Europe Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 12: Europe Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 13: Latin America Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 14: Latin America Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 15: Latin America Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 16: Latin America Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 17: Asia Pacific Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 18: Asia Pacific Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 19: Asia Pacific Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 20: Asia Pacific Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027
      Table 21: Middle East & Africa Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 1, 2016-2027
      Table 22: Middle East & Africa Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 2, 2016-2027
      Table 23: Middle East & Africa Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Segment 3, 2016-2027
      Table 24: Middle East & Africa Pneumonia Vaccines Market Revenue (USD Billion) Forecast, by Country, 2016-2027

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      info@datalibraryresearch.com

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934